Genmab A/S (NASDAQ:GMAB) Rating Lowered to “Underperform” at Sanford C. Bernstein

Genmab A/S (NASDAQ:GMAB) was downgraded by equities research analysts at Sanford C. Bernstein from a “market perform” rating to an “underperform” rating in a report issued on Tuesday, MarketBeat Ratings reports.

Other equities research analysts also recently issued research reports about the stock. BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th. William Blair upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. Truist Financial decreased their price target on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Tuesday, March 11th. Leerink Partnrs upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Finally, Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a research note on Thursday, February 13th. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.33.

Genmab A/S Trading Down 1.6 %

Shares of GMAB stock opened at $19.58 on Tuesday. The company’s 50-day moving average price is $20.87 and its 200-day moving average price is $21.79. Genmab A/S has a twelve month low of $18.64 and a twelve month high of $30.50. The stock has a market cap of $12.96 billion, a price-to-earnings ratio of 11.25, a PEG ratio of 2.65 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, equities research analysts predict that Genmab A/S will post 1.45 EPS for the current year.

Hedge Funds Weigh In On Genmab A/S

A number of hedge funds have recently modified their holdings of the company. EverSource Wealth Advisors LLC lifted its holdings in shares of Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock valued at $26,000 after purchasing an additional 939 shares during the last quarter. Lindbrook Capital LLC raised its holdings in Genmab A/S by 105.4% during the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after acquiring an additional 950 shares during the period. GAMMA Investing LLC boosted its position in shares of Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after acquiring an additional 1,051 shares during the last quarter. Barclays PLC increased its position in shares of Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company’s stock valued at $52,000 after purchasing an additional 2,285 shares during the last quarter. Finally, Cromwell Holdings LLC lifted its holdings in shares of Genmab A/S by 656.8% in the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock worth $60,000 after acquiring an additional 2,496 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.